{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhou B"],"funding":["Shanghai Municipal Health Commission Health Industry Clinical Research Special","Shanghai Municipal Science and Technology Commission","Clinical Key Disease Diagnosis and Treatment Technology Project of Suzhou Municipal Health Commission","Naval Medical University and Eastern Hepatobiliary Surgery Hospital"],"pagination":["oyaf439"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12854084"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(2)"],"pubmed_abstract":["<h4>Background</h4>Sintilimab plus bevacizumab (Sin + Bev) is recommended as a first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, its efficacy remains limited. This study aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) combined with Sin + Bev for HCC with PVTT.<h4>Patients and methods</h4>This retrospective study included 69 HCC patients with PVTT treated at two centers in China from August 2021 to December 2022. Patients received either SBRT + Sin + Bev (n = 31) or Sin + Bev alone (n = 38). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and treatment-related adverse events (TRAEs).<h4>Results</h4>Baseline chara"],"journal":["The oncologist"],"pubmed_title":["Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus."],"pmcid":["PMC12854084"],"funding_grant_id":["20244Y0165","LCZX202235","2022QN098/2022GZR007","22Y11908900"],"pubmed_authors":["Jiang Y","Cheng S","Lu X","Lu Y","Zhou B","Lu C","Ma Z","Wei X","Cheng X","Wang L"],"additional_accession":[]},"is_claimable":false,"name":"Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.","description":"<h4>Background</h4>Sintilimab plus bevacizumab (Sin + Bev) is recommended as a first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, its efficacy remains limited. This study aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) combined with Sin + Bev for HCC with PVTT.<h4>Patients and methods</h4>This retrospective study included 69 HCC patients with PVTT treated at two centers in China from August 2021 to December 2022. Patients received either SBRT + Sin + Bev (n = 31) or Sin + Bev alone (n = 38). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and treatment-related adverse events (TRAEs).<h4>Results</h4>Baseline chara","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-16T03:19:18.754Z","creation":"2026-06-16T03:09:59.599Z"},"accession":"S-EPMC12854084","cross_references":{"pubmed":["41495001"],"doi":["10.1093/oncolo/oyaf439"]}}